GESCO AG

  • WKN: A1K020
  • ISIN: DE000A1K0201
  • Land: Deutschland

Nachricht vom 20.03.2017 | 17:38

GESCO AG plans cash capital increase

Gesco AG / Key word(s): Capital Increase/Capital Increase

20-March-2017 / 17:38 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Wuppertal, 20 March 2017 - The Executive Board of GESCO AG, which is listed in the Prime Standard, plans to conduct a cash capital increase out of the authorised capital of up to 10 % of the share capital at the time of the resolution of the Annual General Meeting on the authorised capital subject to the exclusion of the shareholders' subscription rights and to place the up to 864,499 new shares with institutional investors by means of accelerated bookbuilding. The new shares are expected to have full dividend rights for financial year 2016/2017, meaning from 1 April 2016. The Executive Board and Supervisory Board of GESCO AG are expected to adopt a resolution concerning the implementation of the cash capital increase on 21 March 2017 once investors have been contacted.

equinet Bank AG will be acting as sole lead manager and sole bookrunner for the transaction.

The proceeds from the capital increase will be used to further strengthen GESCO AG's equity following the acquisition of the Pickhardt & Gerlach Group, Finnentrop, which took place in January 2017 and broaden the platform for the further internal and external growth of the GESCO Group.

Important Information:

The information contained in this notification is not for publication or transmission in Canada, Australia or Japan and does not constitute an offer of the purchase of securities in these countries.

The issuing of shares and the distribution of this notification and other information connected with the issuing in certain legal systems may be subject to statutory restrictions and anyone finding themselves in possession of documentation cited in this notification or other information should be informed of and observe all such restrictions. Non-observance of these restrictions may constitute a violation of the Securities Trading Act of the legal system concerned.

This notification does not constitute an offer of the purchase of securities in the United States of America. In the United Kingdom, this notification will only be distributed to (i) professional investors categorised as such under Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and (ii) companies and persons of high net worth categorised as such under Article 49(2)(a) to (d) of the Order (such persons are categorised as "qualified persons"). All securities referred to herein are only available to qualified persons and order, offer or agreement regarding the procurement, purchase or other method of acquisition of such securities shall only be entered into with qualified persons. Persons not categorised as qualified persons should never act in respect of or trust in this notification or its content.

This notification does not constitute an offer of the purchase of securities in Germany and is not classified as a sales prospectus under the Securities Prospectus Act, the European Commission directive No. 809/2004 of 29 April 2004 or any other applicable legal provision governing the issue, offer and sale of securities in Germany.

The information contained in this notification is not for transmission in the United States of America or within the United States of America.

Investor Relations, Oliver Vollbrecht
Tel. +49 202 24820-18, Fax +49 202 24820-49
E-mail: info@gesco.de, Internet: www.gesco.de


20-March-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

EYEMAXX Real Estate AG: EYEMAXX begibt Wandelanleihe im Volumen von bis zu 20,376 Mio. Euro

Kupon:4,5%

Bezugsfrist: bis 12. April 2017 (12.00 Uhr)

Öffentliches Angebot:bis 18. April 2017 (12.00 Uhr)

Laufzeit:bis einschließlich 15. Dezember 2019

ISIN: DE000A2DAJB7

GBC im Fokus

Neovacs S.A.: Kursziel auf 3,30 € angehoben

In den letzten Monaten hatte die Neovacs S.A. einen positiven Newsflow. Im Vordergrund steht die Vertriebspartnerschaft für den chinesischen Markt, wodurch sich bis nach dem ersten Vermarktungsjahr Gesamterträge von bis zu 65 Mio. € ergeben können. Zudem verläuft der klinische Zulassungsprozess des IFNα-Kinoid zur Behandlung von SLE (Systemischer Lupus) und Dermatomyositis planmäßig. Wir haben in unsere Bewertung aktualisiert und ein Kursziel von 3,30 € je Aktie (bisher: 2,90 €) ermittelt. Das Rating lautet weiter KAUFEN.

Event im Fokus

65. m:access Analystenkonferenz

Datum: 06.04.2017
Zeit: 09:30 - 17:00 Uhr
Ort: Börse München
Karolinenplatz 6
80333 München

News im Fokus

Vonovia SE: 93,09 % der conwert-Aktionäre nehmen das Übernahmeangebot von Vonovia an

27. März 2017, 18:18

Aktueller Webcast

Scout24 AG

Full Year Results 2016

29. März 2017

Aktuelle Research-Studie

Ergomed plc

Original-Research: Ergomed plc (von GBC AG): Kaufen

29. März 2017